Neurocrine BiosciencesFRA:NB3 +0.93%95 FCF Margin % is 16.78% as of Mar. 2026, which is 16% below its 10-year median of 19.86. GuruFocus rates FRA:NB3 with a GF Score™ of 95/100 and a GF Value™ of €158.95 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 958 Drug Manufacturers companies, Neurocrine Biosciences ranks better than 94.78% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NB3 vs VTRS, ELAN, RGC: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (FRA:NB3) has a FCF Margin % of 16.78% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Neurocrine Biosciences and its competitors. This is 16% below median its historical median of 19.86. According to the industry distribution chart, Neurocrine Biosciences ranks #50 out of 958 companies in the Drug Manufacturers industry, placing it in the top 5.2%.
Is Neurocrine Biosciences' FCF Margin % too high?
Neurocrine Biosciences' current FCF Margin % of 16.78% is 16% below median its 10-year median of 19.86. The Drug Manufacturers industry median FCF Margin % is 2.51. Neurocrine Biosciences' value of 16.78% is 568.5% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #50 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' FCF Margin % compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #50 out of 958 companies for FCF Margin %. This places Neurocrine Biosciences in the top 5% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.51. Neurocrine Biosciences' value of 16.78% is 568.5% above this benchmark. While the company's 10-year median is 19.86 vs. the industry median of 2.51, Neurocrine Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current FCF Margin % of 16.78% is 568.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current FCF Margin % is 16.78%, which is 16% below median its own 10-year median of 19.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Modestly Undervalued. The stock's GF Value™ is €158.95, compared to a current price of €141.20 — trading 11.2% below its estimated fair value. The current FCF Margin % is 16.78%, which is 16% below median its 10-year median of 19.86 and 568.5% above the Drug Manufacturers industry median of 2.51. Neurocrine Biosciences' overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current FCF Margin % is 16.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of €141.20 is trading 11.2% below its estimated GF Value™ of €158.95.
GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.
Key valuation signals for FRA:NB3:
FCF Margin %: 16.78% (16% below median its 10-year median of 19.86)
GF Value™: €158.95 vs. price of €141.20 (11.2% below fair value)
Industry Position: 568.5% above the Drug Manufacturers median (#50 of 958)
No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
95GF Score
Get the complete analysis for FRA:NB3
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NB3 has been successfully added to your 
